Chemokine News and Research

RSS

Chemokines are a family of small cytokines, or proteins secreted by cells. Proteins are classified as chemokines according to shared structural characteristics such as small size (they are all approximately 8-10 kilodaltons in size), and the presence of four cysteine residues in conserved locations that are key to forming their 3-dimensional shape.

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

Researchers seek to understand causes of premature birth with support from March of Dimes

Five researchers seeking to understand the causes of premature birth with the goal of identifying women at risk of preterm labor and developing new treatments to prevent it have been awarded grant support from the March of Dimes.

10 Mar 2014

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.

15 Jan 2014

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Researchers develop possible new method for treating pancreatic cancer

A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

22 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Type 2 diabetes cytokine elevation places teeth at risk

Scientists have detected significant differences in the cytokine and chemokine make up of gingival crevicular fluid taken from chronic periodontitis patients with uncontrolled Type 2 diabetes and those without.

21 Nov 2013

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

14 Nov 2013

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood.

4 Nov 2013

Research findings offer new therapeutic paradigm for periodontal disease

The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh.

4 Nov 2013

Dunking in tub of ice water post-exercise decreases strength, soreness

Dunking in a tub of ice water after exercise - a surprisingly popular post-workout regimen used by athletes to reduce inflammation and speed recovery - is time consuming and bone-achingly painful. New research from the University of New Hampshire finds that it may not be effective, either.

20 Aug 2013

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Osteoarthritis is an extremely common condition affecting about 8 million people in the UK. The elderly are particularly susceptible, with up to 45% of people over 65 years, having the disease.

14 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Researchers identify new culprit that likely plays big role in severity of asthma

MD-A new culprit has been identified that likely plays a big role in the severity of asthma-a small protein chemokine called CCL26. These findings were published in the Journal of Leukocyte Biology and represent the first demonstration that CCL26 is a potent regulator of the migration of asthmatic eosinophils, commonly observed in asthmatic airways. Results from this discovery may lead to new drug targets for the treatment of asthma.

2 Aug 2013